Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
Drug resistance: Overcoming localized resistance to anti-HER2 therapy Location-specific subpopulations of breast cancer cells adapt to targeted drug treatment, but therapeutic strategies exist to attack these niche-protected cells. A team led by Joan Brugge and Jason Zoeller from Harvard Medical Sch...
Saved in:
Main Authors: | Jason J. Zoeller, Roderick T. Bronson, Laura M. Selfors, Gordon B. Mills, Joan S. Brugge |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/e1b922c7c04a43b2995e897f3abba5b9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
by: Jason J Zoeller, et al.
Published: (2021) -
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
by: Ioannis K. Zervantonakis, et al.
Published: (2017) -
α7 nicotinic acetylcholine receptor upregulation by anti-apoptotic Bcl-2 proteins
by: G. Brent Dawe, et al.
Published: (2019) -
Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
by: Armando Bartolazzi, et al.
Published: (2008) -
Liquiritigenin-Loaded Submicron Emulsion Protects Against Doxorubicin-Induced Cardiotoxicity via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Activity
by: Shi C, et al.
Published: (2020)